A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites
A Phase II, Single-Arm, Open-Label, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Apatinib in Patients With Refractory Malignant Ascites
Sponsor: The First Affiliated Hospital of Bengbu Medical University
This PHASE2 trial investigates Apatinib and Malignant Ascites and is currently ongoing. The First Affiliated Hospital of Bengbu Medical University leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Mar 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2020 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Jun 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The First Affiliated Hospital of Bengbu Medical University
For direct contact, visit the study record on ClinicalTrials.gov .